The problem we are solving:
Most drugs work only on a fraction of the patients, leading to high failure rates of clinical trials and poor efficacy of drugs when delivered to patients. This calls for precision medicine solutions that match the right patient to the right treatment. Combining deep molecular profiling and our unbiased and robust AI discovery platform ScaiVision leads to highly accurate biomarkers and clinically-relevant insights.
90% of clinical trials fail
50% of failed trials lack clinical efficacy
90 / 50
Actionable biomarkers
90% of approved drugs work only in
50% of the patients
What biomarkers are you looking for?
We discover clinically-relevant biomarkers with single-cell analytics and AI
Disease diagnosis
Identify novel biomarkers for an early disease diagnosis
Patient stratification
Identify patients with higher chance to respond to treatment
Mode of Action
Understand the effect on patient’s immune response
Patient monitoring
Identify prognostic and predictive biomarkers
12 successful discovery projects
1000+ single cell samples analyzed
50 Billion data points
We revolutionize biomarker discovery with AI and single-cell data
Single-cell resolution
We harness the richness of single-cell multiomics data to explain complex biological processes
Artificial Intelligence
We apply AI for unbiased, innovative, sensitive, and integrative multiomics data analysis
Biomarker discovery
We deliver translatable biomarker signatures related to therapy response, diagnosis or disease severity
Gain superior speed, robustness, translatability, and unmatched discovery potential
Play Video about Scailyte's Strengths
Faster time-to-insights for accelerated biomarker discovery
Sensitive and specific biomarker discovery to identify clinical biomarkers not achievable by conventional analytics
Fully transparent and explainable results allow the translation of biomarker discoveries into simple, affordable clinical assays
Demonstrated best-in-class AI, ensuring superior robustness and reliability of biomarker discoveries
The discovery and development of biomarkers for precision medicine using single-cell data and AI fully exploits the power of cutting-edge technologies in translational research. We are paving the way for the development of new life-saving diagnostics and next-generation therapeutics for complex diseases.
Partner Testimonials
Meghan Verschoor
Associate Director, Data Science in Clinical and Translational Medicine at Turnstone Biologics
“Our team is very impressed with the level of attention to detail and domain knowledge that the Scailyte team brings to our project. We’re excited to continue working with your team!”
Thomas Mehrling
MD PhD, CEO of MaxiVAX
“Scailyte has been instrumental in analyzing phase IIa clinical single-arm trial data of our most advanced development program. Scailyte’s scientific expertise, communication style and agility are commendable”
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
“Our current collaboration with Scailyte in the field of women’s health is a truly innovative approach. We are integrating cutting edge technologies to develop biomarkers that will be the basis for impactful diagnostic solutions.”
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
“As the co-founder and former CEO of Ava Women, I have experienced the power that big datasets have on the healthcare industry. Scailyte’s mission, proven technology and strong expertise have convinced me to join the team. I am delighted to contribute and assist in bringing Scailyte’s solution to patients around the world.”
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
World CB & CDx Summit 2024
Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...
Recent News
01
/04
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
02
/04
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
03
/04
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
04
/04
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
World CB & CDx Summit 2024
Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...